Medtech Commercial Strategy

Medtech Is Approaching an Inflection Point

The buyers have changed. Many commercial models have not.

I think medtech is approaching an inflection point.

Not because the products are changing. Not because hospitals suddenly buy differently. It’s because the people involved in buying have changed, while many of our commercial models have not.

For years, medtech has been built around a fairly simple idea: find a clinical champion, equip a sales rep, and drive adoption account by account. That model worked because the buying process was often local, relationships carried enormous weight, and a single advocate could move a product forward.

The challenge is that many organizations are still commercializing as though the process looks like this:

That’s where I think the industry is getting stuck.

We continue to ask field sales teams to solve increasingly complex organizational challenges while giving them tools designed for a much simpler buying environment. Then we wonder why sales cycles get longer, why opportunities stall, and why products that seem like obvious wins struggle to gain momentum.

What struck me during our recent Medtech Business Academy discussion was that this isn’t really a sales problem. It’s a visibility problem.

Someone has to understand the entire buying ecosystem. Someone has to identify the stakeholders, understand what they care about, and build a strategy that helps every decision-maker understand where a solution fits. That work doesn’t happen by accident.

Marketing Has to See the Whole Board

This is why I believe marketing is becoming more strategic in medtech. Not because sales is becoming less important, but because somebody has to see the whole board.

The organizations that figure this out first will have an advantage. They’ll spend less time pushing products uphill and more time creating alignment before the sales conversation ever begins.